Osiris Therapeutics, a troubled biotechnology firm based in Columbia, will get another new CEO in July.
The company announced Monday that its board of directors has appointed Linda Palczuk, 55, as president and CEO, effective July 10. After 30 years at AstraZeneca Pharmaceuticals, Palczuk most recently has been a consultat to the pharmaceutical industry.
"I am very excited to join Osiris during this time of transformation," Palczuk said. "I am impressed with the scientific foundation of the company and the current products and emerging pipeline that Osiris offers to patients."
Orisirs also announced that David Dresner is no longer the interim CEO, a position he'd held since June 2016. Jason Keefer, Osiris' vice president of marketing, will serve as interim CEO until Palczuk's arrival.
Keefer will be Osiris' third interim CEO since Lode Debrandere resigned in February 2016 amid allegations of accounting problems at Osiris, which developed the world's first approved stem cell drug.
The company has subsequently restated some financial results and was delisted from the Nasdaq in March. Its shares are now traded over the counter.